Buscapina Plus is a medication indicated for the symptomatic management of pain associated with spasms in various smooth muscle tissues. It is primarily used to alleviate abdominal discomfort or pain that may arise from cramps and spasmodic activity in the gastrointestinal tract.

---

Quick Facts

• Addresses: Spasmodic abdominal pain.
• Relieves: Cramps in the stomach and intestinal areas.
• May help: Manage functional disorders of the biliary and urinary tracts.
• May assist with: Discomfort linked to female genital organs (e.g., dysmenorrhea).

---

This medication may offer a distinct therapeutic approach by combining agents that manage both muscle spasms and associated pain signals. The medication is used in addressing conditions like paroxysmal pain in the stomach or intestine, as well as functional disorders of the biliary, urinary, and female genital organs, such as menstrual cramps. The active ingredients work to reduce the painful contractions of the smooth muscles in these organ systems, offering symptom management for the patient.

Regulatory References

1. EMA therapeutic overview

The eligibility for using Buscapina Plus (Hyoscine Butylbromide and Paracetamol) is strictly governed by regulatory classifications, primarily due to the risk profiles of its two active components.

Contraindicated Populations (Must Not Use)

Use is contraindicated and explicitly prohibited in patients with:

• Known hypersensitivity to the active ingredients or excipients.
• Mechanical stenosis of the gastrointestinal tract, paralytic or obstructive ileus, and megacolon.
• Myasthenia gravis.
• Narrow-angle glaucoma.
• Severe hepatocellular insufficiency (Child-Pugh C).
• Pathological tachyarrhythmia or prostatic hypertrophy with urinary retention.

Age and Physiological Restrictions

Category	Regulatory Status
Children under 10 years	Not suitable for use.
Pregnancy	Not recommended during pregnancy.
Lactation	Not recommended during breastfeeding.

Restricted/Conditional Use

Use is restricted and should proceed with caution in patients with:

• Severe renal insufficiency.
• Hepatic dysfunction (e.g., mild to moderate insufficiency, Gilbert’s syndrome, chronic alcohol use).
• Metabolic conditions like glucose-6-phosphate-dehydrogenase deficiency or low glutathione reserves.

This eligibility profile ensures the medicine is only used by adults and children 10 years and older who do not possess the pre-existing conditions or physiological states that regulatory authorities deem incompatible with the drug's safety profile.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Buscapina Plus based on its two active components: acetaminophen and hyoscine butylbromide.

Pharmacodynamic and Absorption Interactions

Co-administration with medicinal products that possess anticholinergic properties (such as certain antihistamines, tricyclic antidepressants, and antipsychotics) may intensify the effects of hyoscine butylbromide. The product is also documented to interact with dopamine antagonists (e.g., metoclopramide), potentially resulting in a diminution of the effects of both drugs on gastrointestinal motility. This reduction in motility may also delay the systemic absorption and pharmacological effects of other concomitantly administered oral medications.

Exposure, Toxicity, and Contraindicated Combinations

Strict prohibition exists against combining Buscapina Plus with any other medicinal product containing acetaminophen (paracetamol) due to the risk of severe liver damage. The risk of hepatotoxicity is also associated with the concurrent use of the acetaminophen component with alcohol (especially three or more drinks daily) or enzyme-inducing drugs (e.g., phenytoin, carbamazepine, rifampicin). The long-term use of the acetaminophen component with oral anticoagulants (e.g., warfarin) is documented to alter the anticoagulant effect. Additionally, the acetaminophen component is formally restricted in the presence of severe hepatic impairment or severe active liver disease.

Antispasmodic and Analgesic Mechanisms

Buscapina Plus operates through a dual pharmacodynamic mechanism, influencing two distinct physiological pathways: smooth muscle contraction and nociceptive signal transduction.

Antispasmodic Action

The component hyoscine N-butylbromide functions as a peripheral anticholinergic agent. Its action is mediated by the competitive blockade of muscarinic acetylcholine receptors (primarily M3) located on the smooth muscle cells of the gastrointestinal (GI) tract. By preventing the binding of acetylcholine, this component interrupts the efferent neurogenic signaling cascade that initiates excessive smooth muscle contraction. This localized peripheral action contributes to the suppression of elevated muscular tone in visceral organs.

Analgesic Action

Simultaneously, paracetamol modulates central nociceptive signal processing. Its primary mechanism is associated with the modulation of cyclooxygenase (COX) enzymes within the central nervous system (CNS), which results in a modified synthesis of prostaglandins. These lipid mediators enhance pain signaling. The resulting change in prostaglandin levels affects the neural pathways, thereby modifying the sensory threshold for nociception associated with visceral muscular activity.

How to Use Buscapina Plus: Administration Guidelines

The administration of Buscapina Plus (Hyoscine Butylbromide 10 mg / Acetaminophen 500 mg film-coated tablets) follows specific guidelines focusing on precise dosing, frequency, and duration of use.

Administration Scope

Category	Official Instruction
Route of Administration	Oral administration.
Standard Dosing	Adults and Adolescents (10 or 12 years and older): Single dose of 1 to 2 tablets. The total maximum daily dose must not exceed 6 tablets.
Frequency and Timing	Administered up to 3 times daily. A mandatory minimum time interval of 8 hours must be maintained between doses.
Preparation	Tablets must be swallowed whole (unchewed) with an adequate amount of liquid. The score line is not intended for dividing the tablet.

---

Special Procedural Conditions

Duration of Use

The medication is intended solely for short-term, intermittent use for symptomatic relief. It should not be taken continuously for a prolonged period, typically not more than 3 days, without consultation with a prescriber.

Co-Administration Check

To prevent the risk of exceeding the maximum safe limit for the analgesic component, it is a key administration constraint that co-administered medications must be verified to ensure they do not contain Paracetamol (Acetaminophen).

Population Rules

The formulation is not suitable for children under 10 years of age. Patients with known hepatic or renal impairment may require a potential reduced dose or prolonged interval between administrations, typically under professional supervision.

---

Connection to the Use Protocol

These instructions establish a structured protocol that defines the single and daily dose limits, mandates the 8-hour minimum frequency interval, and enforces the short-term duration constraint. This procedural adherence ensures compliance with the maximum allowed exposure to both the antispasmodic and analgesic components.

Research evidence / Overview of Studies for Buscapina Plus

---

Evidence for Primary Dysmenorrhea (Menstrual Cramps)

Research was evaluated in trials exploring conditions characterized by fluctuating or episodic manifestations such as primary dysmenorrhea, commonly known as menstrual cramps. The evidence base includes Randomized Controlled Trials (RCTs), often utilizing double-blind and placebo-controlled designs, alongside observational patient surveys. These studies monitored adult women with primary dysmenorrhea, primarily focusing on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

In these studies, research explored short-term symptom changes following treatment. The findings describe patterns observed in the studies related to how pain and cramp severity was monitored in the study population, typically measured using standardized scales. The body of evidence includes multiple controlled trials and patient surveys which contribute to the broader evidence landscape. Outcomes described was observed in some studies typically within the short, acute treatment window.

---

Evidence for General Spasmodic Abdominal Pain

The combination was studied for conditions associated with acute or disruptive episodes such as spasmodic abdominal pain, which involves symptoms related to smooth muscle activity in the gastrointestinal tract. The evidence includes Randomized Controlled Trials (RCTs) that often compared the combination against placebo or against its single-agent analgesic component (Acetaminophen) alone. Research examined mixed groups of adults presenting with episodic or acute changes in pain, with studies monitoring outcomes like change in pain scores and the need for additional pain relief medication.

Findings describe patterns observed in the studies related to outcomes related to physical discomfort over short-term intervals. However, findings were mixed when the combination was directly compared to taking only the analgesic component, especially in hospital settings for acute, undifferentiated pain. The research base includes evidence derived from settings with varying symptom burdens, which means the evidence quality varies across studies.

---

Key Uncertainties and Research Gaps

Overall, the research helps contextualize how patients reported their experience under specific trial conditions, but it does not determine whether an individual will respond similarly. Key uncertainties stem from the fact that follow-up durations were limited, restricting understanding of long-term patterns. Comparative evidence is lacking against several common analgesic and antispasmodic treatments. Additionally, the high heterogeneity within the spasmodic abdominal pain studies means that evidence quality varies across studies, and further research is needed to refine the understanding of the combination’s role in specific, well-defined painful conditions.

Key Studies & References

1. Hyoscine Butylbromide (Scopolamine Butylbromide) Information and Therapeutic Overview
2. Pharmacovigilance Plan Buscapina Compositum N - Submitted document

Common questions about Buscapina Plus (FAQ)

---

Q: Is Buscapina Plus used for stomach cramps only, or other types of pain too?

A: Official product information describes the use of this medicine for relieving cramp-like pain in the gastrointestinal and genito-urinary tracts. It is also indicated for the symptomatic relief of menstrual cramps. The product is not generally indicated for other types of pain, such as joint or muscle pain, which are not caused by spasms.

Q: How long does the pain relief from Buscapina Plus usually last?

A: Regulatory guidelines require a mandatory minimum time interval of mathbf8 hours between doses, which regulates the maximum use frequency. The two components are absorbed at different rates. The terminal half-life of the antispasmodic component is noted to be approximately 6 to 10 hours, which is a pharmacokinetic measure.

Q: What is the difference between Buscapina Plus and regular Buscapina?

A: Buscapina Plus is defined in official documents as a fixed-dose combination product containing both the antispasmodic Hyoscine Butylbromide and the analgesic Paracetamol. Regular Buscapina typically contains Hyoscine Butylbromide only. The 'Plus' formulation includes both an antispasmodic and an analgesic component.

Q: Is Buscapina Plus appropriate for relieving irritable bowel syndrome (IBS) symptoms?

A: The medicine is indicated for relieving spasmodic abdominal pain related to the gastrointestinal tract. Regulatory documents describe a constraint against the continuous, daily, or prolonged use of symptomatic relief without prior medical investigation into the cause of persistent abdominal pain.

Q: What does 'antispasmodic' mean in simple terms?

A: The antispasmodic part of the medicine refers to the Hyoscine Butylbromide component. This component works by relaxing the smooth muscles in the walls of the digestive and urinary tracts, which relieves the painful, tight contractions or cramps.

Q: Does the use of Buscapina Plus require any dietary restrictions?

A: Official warnings restrict the concurrent use of the Paracetamol component with mathbfalcohol, especially with three or more drinks daily. This restriction is due to an increased risk of liver damage (hepatotoxicity). No other common food or diet restrictions are generally specified in regulatory documents.

Q: Does Buscapina Plus interact with aspirin or other blood-thinning medicines?

A: Official regulatory texts document that the long-term use of the Paracetamol component with oral anticoagulants, such as warfarin, is associated with a potential mathbfalteration of the anticoagulant effect. Specific warnings for aspirin are referenced in the official product information, which can be reviewed for full detail.

Q: How quickly can I expect Buscapina Plus to start working?

A: The two active ingredients have different absorption rates. The analgesic component, Paracetamol, is absorbed quickly and reaches peak concentration in 10 to 60 minutes. The antispasmodic component, Hyoscine Butylbromide, reaches its peak concentration around 2 hours. The onset time of symptom relief can vary for individuals.

Q: Can Buscapina Plus cause drowsiness or make me feel sleepy?

A: Regulatory documents list that the Hyoscine component may cause drowsiness or visual disturbances in some people. Official guidance includes a warning against driving or operating machinery if these effects are experienced.

Q: Has Buscapina Plus been studied in older adults?

A: While specific adverse reactions unique to the elderly population are not reported, official guidelines note that patients with impaired liver or kidney function may require potential dose reductions or prolonged intervals between administrations. Such impairments are common in older adults.

Q: Is there a risk of becoming dependent on Buscapina Plus if I use it often?

A: Official warnings related to frequent use focus on the risk of mathbfrebound,headache or withdrawal symptoms (such as fatigue or nervousness) if analgesic medicines are discontinued abruptly after prolonged, high-dose use. There is no mention of addiction or dependency in the regulatory texts.

Q: What should I do if I forget to take a scheduled dose of Buscapina Plus?

A: General guidance described in patient information indicates continuing with the next scheduled dose when it is due. It is important to ensure that the mathbf8,hour minimum interval between administrations is respected and that a double dose is not taken to compensate for the missed one.

Q: Is Buscapina Plus generally available without a prescription?

A: The official regulatory position is that the product should mathbfnot be taken for more than mathbf3 days without consultation with a physician. This guidance suggests that the initial short-term use may be available without a prescription in many jurisdictions.

Q: Does Buscapina Plus cause constipation?

A: Yes, regulatory documents list constipation as a possible gastrointestinal side effect. It is categorized as an uncommon reaction, meaning it may affect up to 1 in 100 people.

Q: Does Buscapina Plus help with gas and bloating?

A: The medicine's primary indicated purpose is to relieve the mathbfcramp,like,pain caused by smooth muscle spasms. While this mechanism may sometimes help alleviate secondary discomforts like gas and bloating, the product is primarily indicated for the pain itself.

Q: Why do some people say they felt dizzy after taking Buscapina Plus?

A: mathbfDizziness and lightheadedness are listed in regulatory sources as possible side effects. These effects are linked to the properties of the antispasmodic component, Hyoscine Butylbromide.

Q: Is Buscapina Plus safe to take on an empty stomach?

A: Official patient information describes administration as mathbfwith,or,without,food. However, taking the medicine with a heavy meal may slightly delay the absorption of the Paracetamol component.

Q: How is Buscapina Plus eliminated from the body?

A: The two active components are processed differently by the body. The Paracetamol component is primarily mathbfmetabolised,in,the,liver and excreted. The Hyoscine Butylbromide component is mainly eliminated in the mathbffeces via biliary excretion.

Q: Can Buscapina Plus be taken before driving or operating machinery?

A: Regulatory warnings describe that the ability to drive or operate machinery may be affected if side effects such as drowsiness or visual disturbances (like blurred vision) are experienced.

Q: Are the two components of Buscapina Plus released into the body at the same time?

A: The two active components have different pharmacokinetic profiles, which means they are released and processed by the body at different rates. The Paracetamol component is absorbed readily and reaches peak concentration faster (in minutes) than the Hyoscine Butylbromide component (in hours).

The official regulatory information for Buscapina Plus (Hyoscine Butylbromide and Acetaminophen) defines strict requirements for its storage and disposal.

Storage Requirements

• Temperature: Store at temperatures not exceeding 30 C or as specified by the regional label. The product must be protected from heat.
• Packaging: Keep the tablets in the original package to ensure protection from light and moisture, maintaining product stability until the expiry date.
• Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

• Expiration: Do not use the medicine after the printed expiry date.
• Environment: Do not throw away any unused or expired product via wastewater or household waste.
• Protocol: Disposal must be done in accordance with local regulations, typically requiring users to ask a pharmacist for the proper method to discard the medicine.